Eli Lilly targets alleged black market sales of its experimental GLP-1 drug

Another front in the weight-loss drug wars: Eli Lilly is suing six entities peddling black market retratutide, its experimental GLP-1 candidate. As The Hill reports, these sellers—compounding pharmacies, medical spas, online hucksters—use "research-use only" as a wink for unverified injections. This isn't just a corporate beef; it's public health triage. Both sides deserve scrutiny. Lilly has legitimate claims: unapproved, unregulated drugs can be dangerous, and protecting trial data is fair. But the black market doesn't exist in a vacuum. High prices, limited supply, and relentless demand for weight-loss hacks fuel this gray economy. When patients can't access legitimate care, they gamble. This signals a regulatory tightrope: how do we balance safety with desperation? Lawsuits may shut down sellers, but they won't cure the demand that births them. Lilly could score legal wins while losing public trust if it reads as profit over access. Closer: The needle moves fastest when it's pushed by hope—just remember, cheap "hacks" often carry the highest hidden cost. {"key_insight":"Black markets thrive on regulatory gaps and patient desperation, not just moral failure.","confidence":0.6}